Beacon Pointe Advisors LLC decreased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 16.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 310,941 shares of the biopharmaceutical company's stock after selling 59,517 shares during the quarter. Beacon Pointe Advisors LLC's holdings in Bristol-Myers Squibb were worth $15,954,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also modified their holdings of BMY. Northern Trust Corp boosted its position in Bristol-Myers Squibb by 5.8% during the third quarter. Northern Trust Corp now owns 25,292,711 shares of the biopharmaceutical company's stock valued at $1,467,989,000 after purchasing an additional 1,394,158 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Bristol-Myers Squibb by 7.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 16,959,807 shares of the biopharmaceutical company's stock valued at $870,198,000 after purchasing an additional 1,246,066 shares during the last quarter. Invesco Ltd. boosted its position in Bristol-Myers Squibb by 8.6% during the third quarter. Invesco Ltd. now owns 15,606,587 shares of the biopharmaceutical company's stock valued at $905,806,000 after purchasing an additional 1,240,902 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Bristol-Myers Squibb by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 11,361,717 shares of the biopharmaceutical company's stock valued at $582,970,000 after purchasing an additional 134,815 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its position in shares of Bristol-Myers Squibb by 48.0% in the fourth quarter. Pacer Advisors Inc. now owns 7,830,948 shares of the biopharmaceutical company's stock worth $401,806,000 after buying an additional 2,540,360 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.
Bristol-Myers Squibb Price Performance
BMY stock traded down $0.44 during trading on Thursday, hitting $44.11. The company had a trading volume of 15,765,096 shares, compared to its average volume of 15,553,328. The company has a fifty day moving average price of $49.29 and a two-hundred day moving average price of $50.09. Bristol-Myers Squibb has a fifty-two week low of $43.33 and a fifty-two week high of $67.35. The company has a market cap of $89.42 billion, a P/E ratio of -14.14, a P/E/G ratio of 15.23 and a beta of 0.45. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.
Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm's quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.05 EPS. Equities research analysts expect that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.
Bristol-Myers Squibb Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.44%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently -77.42%.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on BMY. Wells Fargo & Company boosted their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an "equal weight" rating in a research report on Thursday, April 18th. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. StockNews.com cut Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Monday, April 15th. Barclays reduced their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an "equal weight" rating for the company in a research report on Friday, April 26th. Finally, Societe Generale downgraded Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research note on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $60.00.
Read Our Latest Stock Report on Bristol-Myers Squibb
About Bristol-Myers Squibb
(
Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bristol-Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.
While Bristol-Myers Squibb currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
